CoChat

Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody

Open access

Published version of a preprint

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Purpose: Myeloid-derived suppressor cells (MDSC) are one of the major contributors to immune suppression in cancer. We recently have demonstrated in preclinical study that MDSCs are sensitive to TRAIL receptor 2 (TRAIL-R2) agonist. The goal of this study was to clinically test the hypothesis that targeting TRAIL-R2 can selectively eliminate MDSCs. Experimental Design: The TRAIL-R2 agonistic antibody (DS-8273a) has been tested in 16 patients with advanced cancers enrolled in a phase I trial. The antibody (24 mg/kg) was administered intravenously once every 3 weeks till disease progression, unacceptable toxicities, or withdrawal of consent. The safety and the presence of various populations of myeloid and lymphoid cells in peripheral blood and tumor tissues were evaluated. Results: The treatment was well tolerated with only mild to moderate adverse events attributable to the study drug. Treatment with DS-8273a resulted in reduction of the elevated numbers of MDSCs in the peripheral blood of most patients to the levels observed in healthy volunteers. However, in several patients, MDSCs rebounded back to the pretreatment level by day 42. In contrast, DS-8273a did not affect the number of neutrophils, monocytes, and other populations of myeloid and lymphoid cells. Decrease in MDSCs inversely correlated with the length of progression-free survival. In tumors, DS-8273a treatment resulted in a decrease of MDSCs in 50% of the patients who were able to provide pre- and on-treatment biopsies. Conclusions: Targeting TRAIL-R2 resulted in elimination of different populations of MDSCs without affecting mature myeloid or lymphoid cells. These data support the use of this antibody in combination immmunotherapy of cancer. Clin Cancer Res; 23(12); 2942–50. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-1784

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Research works printed but not linked: 1

  1. Solito, 2014, Myeloid-derived suppressor cell heterogeneity in human cancers, Ann NY Acad Sci, 1319, 47, 10.1111/nyas.12469 · DOI · Paper page

Cited by

See all 187

Metadata

Authors
Dominguez, G. A., Condamine, T., Mony, S., Hashimoto, A., Wang, F., Liu, Q., Forero, A., Bendell, J., Witt, R., Hockstein, N., Kumar, P., & Gabrilovich, D. I.
Affiliations
  • The Wistar Institute (US)
  • University of Alabama at Birmingham (US)
  • Tennessee Oncology (US)
  • Christiana Care Health System (US)
  • Daiichi Sankyo (United States) (US)
Corresponding author
Gabrilovich, Dmitry I.
Venue
Clinical Cancer Research
Published
2017-06-14
Volume
23
Issue
12
Pages
2942-2950
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2564668537
Cited by
187
References
32
Citations by year
2026: 5 · 2025: 24 · 2024: 23 · 2023: 16 · 2022: 23 · 2021: 27 · 2020: 22 · 2019: 19 · 2018: 18 · 2017: 9
FWCI
9.29
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
Daiichi Sankyo NIH (CA084488)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
myeloid-derived suppressor cells, DR5, agonistic antibodies, cancer immunotherapy, tumor immunosuppression, safety and tolerability, progression-free survival, tumor-infiltrating myeloid cells
MeSH terms
Myeloid-Derived Suppressor Cells, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humans, Immunosuppression Therapy, Immunotherapy, Lymphocyte Activation, Middle Aged, Monocytes, Neoplasms, Disease-Free Survival, Myeloid Cells, Receptors, TNF-Related Apoptosis-Inducing Ligand

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-1784
The paper
Dominguez, G. A., Condamine, T., Mony, S., Hashimoto, A., Wang, F., Liu, Q., Forero, A., Bendell, J., Witt, R., Hockstein, N., Kumar, P., & Gabrilovich, D. I. (2017). Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-1784

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.